Phase II Trial of Sorafenib (BAY 43-9006) (IND 69896; NSC 724772) in Patients With Advanced Urothelial Cancer.

Trial Profile

Phase II Trial of Sorafenib (BAY 43-9006) (IND 69896; NSC 724772) in Patients With Advanced Urothelial Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Urogenital cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 13 Nov 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jan 2008 Status change from recruiting to in progress, from nct record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top